Jill Rachel Mains

Jill Rachel Mains

Auto-generated profile, based on publicly available information

Jill Rachel Mains

Aarhus University Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Investigative Radiology
Verified
Journal Article
Closed access
JMJill Rachel Mains
Jill Rachel Mains
FDFrede Donskov
Frede Donskov
EPErik Morre Pedersen
Erik Morre Pedersen
HMHans Henrik Torp Madsen
Hans Henrik Torp Madsen
FRFinn Rasmussen
Finn Rasmussen
The aim of this study was to explore the impact of dynamic contrast-enhanced (DCE) computer tomography (CT) as a biomarker in metastatic renal cell carcinoma (mRCC). Twelve patients with favorable or intermediate Memorial Sloan Kettering Cancer Center risk group and clear cell mRCC participating in an ongoing prospective randomized phase II trial comprising interleukin-2-based immunotherapy and bevacizumab were included in this preliminary analysis. All patients had a follow-up time of at least 2 years. Interpretation of DCE-CT (max slope method) was performed blinded to treatment group. The DCE-CT scans were performed at baseline, at weeks 5 and 10, and thereafter every third month. Blood flow (BF; mL/min/100 mL), peak enhancement (Hounsfield units), time to peak (seconds), and blood volume (BV; mL/100 g) were calculated. Parameters for DCE-CT were correlated with sum of diameters (defined by Response Evaluation Criteria in Solid Tumors 1.1), progression-free survival (PFS), and overall survival (OS) using Wilcoxon, Man-Whitney, Kaplan-Meier, and log rank statistics, as appropriate. Blood flow at baseline ranged from 4.9 to 148.1 mL/min/100 mL (median, 62.2; 25th percentile, 25.8; 75th percentile, 110.0). Patients with high baseline BF (using quartiles as cutoffs) had significantly longer OS (not reached vs 5.2 months, P = 0.011) and longer PFS (not reached vs 3.9 months, P = 0.026). Blood volume at baseline ranged from 8.8 to 74.1 mL/100 g tissue (median, 21.5), and at week 5, from 4.9 to 34.7 mL/100 g (median, 17.2). Relative changes in BV between baseline and week 5 ranged from -64% to +68% (median, -16%; 25th percentile, -41%; 75th percentile, +2%) and were significantly associated with OS using quartiles as cutoffs (5.2 months vs not reached, P = 0.038) and PFS using the median as cutoff (5.3 months vs not reached, P = 0.009), with larger reductions associated with longer survival. Using medians as cutoffs, relative changes in both BF and BV between baseline and week 10 were significantly associated with OS (for both, 8.6 months vs not reached, P = 0.031). Dynamic contrast-enhanced CT is a potential biomarker in patients with mRCC. High baseline BF and reductions in BF and BV during early treatment are associated with improved outcome. Large-scale studies are required.

1 February 2017 in Investigative Radiology
Verified
Journal Article
Closed access
JMJill Rachel Mains
Jill Rachel Mains
FDFrede Md Donskov
Frede Md Donskov
EPErik Morre MD Pedersen
Erik Morre MD Pedersen
HMHans Henrik Torp Madsen
Hans Henrik Torp Madsen
FRFinn Md Rasmussen
Finn Md Rasmussen
Objectives: The aim was to explore the potential for using dynamic contrast-enhanced computed tomography as a noninvasive functional imaging biomarker before and during the early treatment of metastatic renal cell carcinoma (mRCC). Materials and Methods: Dynamic contrast-enhanced computed tomography scans were performed at baseline and after 5 and 10 weeks' treatment in 69 prospectively included mRCC patients receiving treatment with interferon alpha and interleukin 2 (n = 26); interferon alpha, interleukin 2, and bevacizumab (n = 24); sunitinib (n = 7); pazopanib (n = 5); or temsirolimus (n = 7). Using a prototype software program (Advanced Perfusion and Permeability Application, Philips Healthcare, Best, the Netherlands), blood volume (BV), blood flow (BF), and permeability surface area product (PS) were calculated for each tumor at baseline, week 5, and week 10. These parameters as well as relative changes between baseline and weeks 5 and 10 were tested for associations with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. Results: Using the 25th percentile as the cutoff, baseline BV for all patients independent of subsequent treatment was statistically significantly associated with PFS (10.8 vs 5.3 months, P = 0.007) and OS (35.2 vs 13.3 months, P = 0.001), and baseline BF was significantly associated with OS (31.7 vs 14.6 months, P = 0.024) with high values for both parameters being associated with significantly longer PFS and OS. Baseline PS was not associated with PFS or OS. In patients treated with angiogenesis inhibitors (bevacizumab, sunitinib, pazopanib, or temsirolimus), the relative change in BV from baseline to week 5 using 25th percentile as the cutoff was associated with PFS (5.6 vs 24.8 months, P = 0.001) and OS (19.1 months vs not reached, P = 0.008) and from baseline to week 10 with PFS (8.1 vs 16.4 months, P = 0.014) and OS (15.5 months vs not reached, P = 0.002). The relative change in BF from baseline to week 5 using medians as the cutoff was associated with PFS (5.5 vs 14.3 months, P = 0.018) and OS (14.6 vs 31.7 months, P = 0.027). The relative change in BF from baseline to week 10 using 25th percentile as the cutoff was associated with PFS (8.3 vs 46.9 months, P = 0.011) and OS (19.1 vs 53.0 months, P = 0.006). For both parameters, the largest reductions during early treatment were associated with increased PFS and OS. In patients receiving immunotherapy only (interferon alpha and interleukin 2), relative changes in PS between baseline and weeks 5 and 10 were significantly associated with PFS with larger increases associated with longer PFS. In patients receiving angiogenesis inhibitors, the relative changes in PS between baseline and week 10 were significantly associated with PFS and OS with larger reductions associated with favorable outcomes. Conclusions: In patients with mRCC treated with angiogenesis inhibitors, the largest reductions in BV and BF between baseline and weeks 5 and 10 were associated with favorable outcomes. At baseline, the lowest BV and BF were associated with the poorest outcomes regardless of the subsequent treatment. Early reductions in PS were associated with favorable outcomes for those treated with angiogenesis inhibitors and with poor outcomes for those treated with immunotherapies.

1 December 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
JMJill Rachel Mains
Jill Rachel Mains
FDFrede Donskov
Frede Donskov
EPErik Morre Pedersen
Erik Morre Pedersen
HMHans Henrik Torp Madsen
Hans Henrik Torp Madsen
JTJesper Thygesen
Jesper Thygesen
FRFinn Rasmussen
Finn Rasmussen
Objective: To use the patient outcome endpoints overall survival and progression-free survival to evaluate functional parameters derived from dynamic contrast-enhanced CT. Methods: 69 patients with metastatic renal cell carcinoma had dynamic contrast-enhanced CT scans at baseline and after 5 and 10 weeks of treatment. Blood volume, blood flow and standardized perfusion values were calculated using deconvolution (BVdeconv, BFdeconv and SPVdeconv), blood flow and standardized perfusion values using maximum slope (BFmax and SPVmax) and blood volume and permeability surface area product using the Patlak model (BVpatlak and PS). Histogram data for each were extracted and associated to patient outcomes. Correlations and agreements were also assessed. Results: The strongest associations were observed between patient outcome and medians and modes for BVdeconv, BVpatlak and BFdeconv at baseline and during the early ontreatment period (p < 0.05 for all). For the relative changes in median and mode between baseline and weeks 5 and 10, PS seemed to have opposite associations dependent on treatment. Interobserver correlations were excellent (r ≥ 0.9, p < 0.001) with good agreement for BFdeconv, BFmax, SPVdeconv and SPVmax and moderate to good (0.5 < r < 0.7, p < 0.001) for BVdeconv and BVpatlak. Medians had a better reproducibility than modes. Conclusion: Patient outcome was used to identify the best functional imaging parameters in patients with metastatic renal cell carcinoma. Taking patient outcome and reproducibility into account, BVdeconv, BVpatlak and BFdeconv provide the most clinically meaningful information, whereas PS seems to be treatment dependent. Standardization of acquisition protocols and post-processing software is necessary for future clinical utilization. Advances in knowledge: Taking patient outcome and reproducibility into account, BVdeconv, BVpatlak and BFdeconv provide the most clinically meaningful information. PS seems to be treatment dependent.

6 August 2023 in Acta Radiologica
Verified
Journal Article
Closed access
ADAska Drljevic-Nielsen
Aska Drljevic-Nielsen
NSNikolaj Skou
Nikolaj Skou
JMJill R Mains
Jill R Mains
EPErik M Pedersen
Erik M Pedersen
FRFinn Rasmussen
Finn Rasmussen
FDFrede Donskov
Frede Donskov
Background: A higher incidence of late adverse events (LAEs) to iodinated contrast media in interleukin-2 (IL-2)-treated patients has been reported. Purpose: To assess the incidence of LAEs after administration of iodinated contrast media in patients with metastatic renal cell carcinoma (mRCC) treated with IL-2. Material and Methods: Patients were randomized to treatment with IL-2 and interferon-α with/without bevacizumab in the Danish Renal Carcinoma Group study – 1. Patients underwent a computed tomography (CT) scan at baseline, at one month, at three months, and every third month until RECIST 1.1 defined progression. LAEs due to iodinated contrast media were systematically registered according to the Common Terminology Criteria for Adverse Events classification. Results: In total, 89 patients were included and underwent a total of 507 contrast-enhanced CT scans. An overall incidence of 46 (9.1%) LAEs was observed in 38 of 89 (42.7%) patients; 3 LAEs at baseline (3.4% of all baseline scans), 39 (13.9%) LAEs during IL-2-based therapies, and 4 (2.9%) LAEs after termination of IL-based therapies. There was no difference in progression-free survival, overall survival, and treatment response in patients experiencing LAEs compared to patients without LAEs ( P = 0.2, P = 0.5, and P = 0.6, respectively). Conclusion: Patients with mRCC demonstrated a higher incidence of LAEs after administration of iodinated contrast during ongoing IL-2 therapy, indicating that iodinated contrast media may cause a recall phenomenon of IL-2 toxicities in patients with mRCC. Treatment with IL-2 should not be a contraindication for contrast-enhanced scans in patients with mRCC but expertise and vigilance are required.

26 August 2025 in Acta Radiologica
Verified
Journal Article
Closed access
TBThomas Winther Buus
Thomas Winther Buus
JMJill Rachel Mains
Jill Rachel Mains
AJAnders Bonde Jensen
Anders Bonde Jensen
EPErik Morre Pedersen
Erik Morre Pedersen
Background: Treatment response assessment can be challenging in bone-metastasizing breast cancer. Whole-body magnetic resonance imaging (WB-MRI) is superior to contrast-enhanced computed tomography (CE-CT) for detecting progressive disease (PD) in bone-only metastatic breast cancer; however, the ability to detect PD in mixed visceral- and bone-metastasizing breast cancer remains to be assessed in prospective studies. Purpose: To prospectively compare WB-MRI and CE-CT for detecting PD in mixed visceral- and bone-metastasizing breast cancer and determine if WB-MRI could detect PD earlier than CE-CT. Material and Methods: A total of 43 women with mixed visceral- and bone-metastasizing breast cancer were prospectively followed with WB-MRI and CE-CT from the initiation of new chemotherapy. Kaplan–Meier analysis of time to progression was performed for both WB-MRI and CE-CT, and the time difference between the two was compared using a one-sample t -test. The ability to detect PD earliest was compared using McNemar’s test. Results: Of the 43 patients enrolled, 21 completed the study. Treatment was changed due to PD in 18 patients and due to side effects in three patients. Median time until change of treatment was 8 months (range=4–21 months). WB-MRI correctly detected PD in 16/18 patients compared to 13/18 for CE-CT. A total of 73 pairs of examinations were analyzed, of which WB-MRI detected PD earliest in 7/18 patients compared to 1/18 for CE-CT ( P = 0.035).. There were no statistically significant differences in time to progression between WB-MRI and CE-CT ( P = 0.41). Conclusion: WB-MRI can detect PD in women with mixed visceral- and bone-metastasizing breast cancer earlier than CE-CT.